We are pleased to share that CEO.ca has issued a press release as part of its latest Inside the Boardroom series, featuring Rapid Dose Therapeutics.

In June, QuickStrip™ by Rapid Dose Therapeutics was featured in RecoverCann’s WGY6 campaign for Men’s Mental Health and PTSD Awareness Month—spotlighting wellness-oriented innovations.

This visibility aligns with a major research milestone: QuickStrip™ is currently being studied in an NFL-funded clinical trial, led by researchers at the University of Regina and the University of Saskatchewan. The study is evaluating the pharmacokinetics of CBD when delivered through RDT’s QuickStrip™ compared to traditional oral formats. The strips are rectangular oral thin films infused with cannabis extract, which, when placed under the tongue, dissolve and release the cannabis extract into the mucus membranes of the mouth.

You can read the full press release here:
https://pro.ceo.ca/@newsfile/ceocas-inside-the-boardroom-rapid-doses-drug-delivery

About Rapid Dose Therapeutics Corp.
Rapid Dose Therapeutics is a Canadian biotechnology company revolutionizing drug delivery through innovation. The Company’s flagship product QuickStrip™ is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients, including nutraceuticals, pharmaceuticals and vaccines, that are delivered quickly into the bloodstream, resulting in rapid onset of the active ingredient.
For more information about the Company, visit www.rapid-dose.com.

Contacts:
Mark Upsdell, CEO
investorrelations@rapid-dose.com
416-477-1052